REGENERON PHARMACEUTICALS, INC. Adjustments to Additional Paid in Capital, Other
REGENERON PHARMACEUTICALS, INC. (REGN) reported Adjustments to Additional Paid in Capital, Other of -$643.30 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-07.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2014-12-31 was -$151.51M.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for the quarter ending 2014-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2016 was -$643.30M.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2015 was -$449.46M.
- REGENERON PHARMACEUTICALS, INC. adjustments to additional paid in capital, other for fiscal 2014 was -$294.55M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month | Adjustments to Additional Paid in Capital, Other 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | -$643.30M 10-K · filed 2019-02-07 | -$643.37M 10-K · filed 2017-02-09 | |||
| 2015-12-31 | -$449.46M 10-K · filed 2018-02-08 | ||||
| 2014-12-31 | -$151.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | -$151.51M derived: sum of 2 quarters · filed 2017-02-09 | -$294.55M 10-K · filed 2017-02-09 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$143.04M 10-Q · filed 2014-11-04 | |||
| 2014-06-30 | -$143.04M 10-Q · filed 2014-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |